Global healthcare expenditure is increasing [1] , creating budget pressures and challenging market access for an increasing number of drugs [2] . For instance, from 1998-2008, NICE granted restricted or no access to ~60% of drugs from the top 10 Pharma and since 2004, IQWiG classified 70% of reviewed drugs as "benefit not proven" [3] . Payers are often bewildered by decisions made by pharmaceutical manufacturers when designing their clinical trials, choosing their comparators, or making certain safety and efficacy claims with mismatched evidence. This misalignment may be the result of clinical development plans focused on regulatory compliance that do not fully consider the real-world patient populations that reflect Payer's chief concerns. Not engaging Payers as early as possible during the asset development process could result in delay of approval and/or rejection of reimbursement. Knowledge of payer priorities and the level of evidence they seek are crucial to characterization of real value of assets and competitive differentiation. The objective of this study was to illustrate the case for early payer engagement to ensure optimal patient access to differentiated assets. We here present the relative merits of various approaches to engage with Payers as well as case studies exemplifying the positive impact of early engagement.
1.We conducted primary research with internal industry experts (Quintiles internal network of market access subject matter experts) in the U.S. and EU to identify best approaches for collaboration.
2. We conduct secondary market research and a literature review to identify success stories for cross-industry collaboration across the US, Canada and 5 EU (France, Italy, Germany, Spain, UK).
Publications in English published since 2009 were identified using sources such as: Conference transcripts, HTA and policy papers, Governmental documentation of EPE processes and meeting requirements/steps (e.g., CMS, CADTH, NICE, G-BA, HAS), Relevant news articles and financial analyst reports, Other published literature such as that found on Cochrane, PubMed or MEDLINE.
• There are multiple strategies that can be employed in early payer engagement ranging from scientific advice to shape the asset development plan to planning for risk sharing agreements when agreement cannot be reached on price or on the reimbursement terms or stakeholder partnerships to uncover the real-world value of innovative products. The approach can be formal or informal direct to payer consultations to incorporation of various levels of data collection in the development strategy from interviews to advisory boards. (Figures 1 and Table 1 ). While direct to Payer consultations often happen prior to formal submission, risk sharing agreements and partnerships, when they are appropriate, should be planned at an early stage for optimal benefits.
• Based on a Quintiles-led survey of managed care executives in the US and NHS executives in the UK, 43%of UK Payers said they should be involved in early stages of drug development, but only 18% reported currently being involved at this stage. Payers in both countries were interested (61%of US Payers and 70%of UK Payers) in involvement at the Phase III/pivotal study design stage which they perceive as the primary area to influence the evidence base surrounding an asset [ Figure 2 ] [4] . Payers from the UK, Canada, Australia and France were open to engagement as early as the end of Phase I, while Payers from Spain and Italy who requested additional economic evidence wanted to engage in Phase II and early Phase III. US Payers considered the benefits of engagements at all stages of clinical development. In emerging markets, the engagement landscape is more nascent and evolving, though it may often include informal payer consultation and risk sharing negotiations.
• We have provided case studies where early payer engagement has led to a favorable market access situation (Table 3 ). In the UK, early engagement has involved both formal payer consultations, and risk sharing agreements, but NHS or CCGs are now pushing for long term real world health outcomes and performance linked reimbursement. Germany ties asset price to evidence of additional benefit accepting both risk-sharing schemes and value based pricing. CADTH and Australia are expanding risk-sharing deals and patient group testimony ensuring that patient-reported outcomes and concerns are incorporated into approval and coverage decisions. For instance, early engagement may help identify payers concerns early and ensure appropriate RWE strategy such as was the case when the SMC rejected Versatis pain patch for coverage over concerns about over usage and high expense. The manufacturer then conducted physician survey to get approval 1.5 years after submission. In another case, early engagement with the Dutch national insurer led to an innovative Performance Linked reimbursement scheme to reduce access barriers for Pradaxa in the Netherlands. (Table 3 )
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Incorporating clear understanding of stakeholder's requirements into asset development plans early in product development can help the manufacturer achieve a reimbursable file in an increasingly restrictive environment and avoid access delays. Early engagement also helps the manufacturer identify whether additional requirements or tactics such as risk sharing, conditional coverage, contracting are viable for a particular asset. While early payer engagement was an uncertainty a decade ago, today Payer expectations for more involvement in evidence development represent a key opportunity for manufacturers to identify differentiation requirements. Knowledge of payer priorities and the level of evidence they seek are crucial to manufacturers when facing increasing drug development costs and uncertain market outcomes. Integration of early payer engagement into typical asset development cascades that involve market research and refinement of value strategies through ad boards and other vehicles can help manufacturers to refine and plan for optimal value proposition development, avoid some evidence development pitfalls, and in some cases prevent delays or rejections in a way that more tangential approaches cannot. 
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